Macy's Inc vs Medtronic PLC — how do they compare? Macy's Inc trades at $22.93 (market cap $5.95B), while Medtronic PLC trades at $88 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 18.9× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Medtronic PLC for 63 Days on average.
| M | MDT | |
|---|---|---|
Market Cap | $5.95B | $112.24B |
Volume | 6,030,644 | 105,663,236 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $105.35 |
52-Week Low | $16.51 | $73.75 |
Typical Hold Time | 58 Days | 63 Days |
Enterprise Value | $9.75B | $131.58B |
Dividend Yield | 3.36% | 3.28% |
Signals from Pluang's Aura AI — not financial advice
Macy's stock trades at $22.61, down 0.79% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and a 'Bold New Chapter' strategy driving digital transformation. Valuation metrics appear attractive with P/E of 8.35 and P/S of 0.27, while profitability shows recovery with ROE of 15.99% and net margin improvement to 3.29%.
The outlook remains cautiously optimistic with analyst consensus at $24.25 representing 7% upside potential. Key opportunities include digital growth initiatives and dividend sustainability, while risks involve retail sector headwinds and uneven quarterly performance. The stock offers value characteristics with turnaround potential, supported by improved cash flow generation and balance sheet strength.
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →